2 weeks Ago By ABMN Staff
Cassava Sciences, Inc. ( NASDAQ:SAVA – Get Free Report )’s stock price gapped down before the market opened on Friday . The stock had previously closed at $31.
87, but opened at $28.08. Cassava Sciences shares last traded at $28.
69, with a volume of 1,769,883 shares traded. Analyst Upgrades and Downgrades Several research analysts recently issued reports on SAVA shares. HC Wainwright reissued a “neutral” rating on shares of Cassava Sciences in a research note on Tuesday, August 13th.
Rodman & Renshaw reaffirmed a “buy” rating and issued a $107.00 price objective on shares of Cassava Sciences in a research note on Thursday, August 8th. View Our Latest Stock Report on Cassava Sciences Cassava Sciences Price Performance Cassava Sciences ( NASDAQ:SAVA – Get Free Report ) last posted its earnings results on Thursday, August 8th.
The company reported $0.13 EPS for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.
57. During the same quarter in the previous year, the firm posted ($0.63) EPS.
Equities analysts anticipate that Cassava Sciences, Inc. will post -5.7 EPS for the current fiscal year.
Institutional Trading of Cassava Sciences Institutional investors have recently bought and sold shares of the stock. EntryPoint Capital LLC grew its holdings in shares of Cassava Sciences by 1,251.2% during the first quarter.
EntryPoint Capital LLC now owns 2,297 shares of the company’s stock valued at $47,000 after buying an additional 2,127 shares during the last quarter. Dark Forest Capital Management LP purchased a new stake in Cassava Sciences in the second quarter valued at approximately $131,000. Arizona State Retirement System raised its position in Cassava Sciences by 4.
2% during the 2nd quarter. Arizona State Retirement System now owns 11,495 shares of the company’s stock worth $142,000 after buying an additional 468 shares during the last quarter. NBC Securities Inc.
lifted its stake in Cassava Sciences by 9.3% during the 1st quarter. NBC Securities Inc.
now owns 7,650 shares of the company’s stock valued at $155,000 after acquiring an additional 650 shares during the period. Finally, Profund Advisors LLC boosted its holdings in shares of Cassava Sciences by 4.6% in the 2nd quarter.
Profund Advisors LLC now owns 13,440 shares of the company’s stock valued at $166,000 after acquiring an additional 591 shares during the last quarter. 38.05% of the stock is currently owned by institutional investors and hedge funds.
Cassava Sciences Company Profile ( Get Free Report ) Cassava Sciences, Inc, a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. Read More Receive News & Ratings for Cassava Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cassava Sciences and related companies with MarketBeat.
com's FREE daily email newsletter ..
